HALB (Halberd) Earnings per Share (Diluted) : $ (TTM As of Jul. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Halberd Earnings per Share (Diluted)?

Halberd's Earnings per Share (Diluted) for the six months ended in Jul. 2023 was $-0.00.

Halberd's EPS (Basic) for the six months ended in Jul. 2023 was $-0.00.

Halberd's EPS without NRI for the six months ended in Jul. 2023 was $-0.00.

Halberd Earnings per Share (Diluted) Historical Data

The historical data trend for Halberd's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Earnings per Share (Diluted) Chart

Halberd Annual Data

Trend

Jul08

Jul22

Jul23

Earnings per Share (Diluted)

Halberd Semi-Annual Data
	Jul08	Jul22	Jul23
Earnings per Share (Diluted)	-	-	-

Competitive Comparison of Halberd's Earnings per Share (Diluted)

For the Biotechnology subindustry, Halberd's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's PE Ratio distribution charts can be found below:

* The bar in red indicates where Halberd's PE Ratio falls into.

Save Embed

;

Save Embed

;

Halberd Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Halberd's Earnings Per Share (Diluted) for the fiscal year that ended in Jul. 2023 is calculated as

Diluted Earnings Per Share (A: Jul. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-0.454	-	0)	/	537.108
	=	-0.00

Halberd's Earnings Per Share (Diluted) for the quarter that ended in Jul. 2023 is calculated as

Diluted Earnings Per Share (Q: Jul. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-0.454	-	0)	/	537.108
	=	-0.00

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Halberd (OTCPK:HALB) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Halberd Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Halberd's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Halberd Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 25, Jackson Center, PA, USA, 16133

Website

https://www.halberdcorporation.com

Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.

Executives

John Christopher Maddox	director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO	10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist	director, 10 percent owner, officer: CEO, Secretary and Director	24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr.	director	50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas	director	280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236